Abstract
Sleep disorders are disturbances of usual sleep patterns or behaviors caused by deregulation of neuronal synchronicity and of the balance of the neurotransmitter system involved in sleep regulation. Insomnia and hypersomnia are frequent sleep disorders, and these are most often treated pharmacologically with hypnotics and wake-promoting compounds. These compounds act on classical neurotransmitter systems, such as benzodiazepines on gamma amino butyric acid (GABA)A receptors, and amphetamine-like stimulants on monoaminergic terminals to modulate neurotransmission. In addition, acetylcholine, amino acids, lipids and proteins (cytokines) and peptides, are known to significantly modulate sleep, and thus, are possibly involved in the pathophysiology of some sleep disorders. Due to recent developments in molecular biological techniques, many neuropeptides have been newly identified, and some are found to significantly modulate sleep. Recent discoveries also include the finding that the impairment of hypocretin/orexin neurotransmission (a recently isolated hypothalamic neuropeptide and receptor system), is the major pathophysiology of narcolepsy with cataplexy. A hypocretin replacement therapy is anticipated to reverse the disease symptoms in humans. In this article, we will review the history of neuropeptide research, sleep modulatory effects of various neuropeptides, and the general strategies for the pharmacological therapeutics targeting the peptidergic systems by referring to hypocretin-deficient narcolepsy as an immediate example.
Keywords: Sleep disorders, neuropeptide, GPRC, hypocretin, orexin, narcolepsy
CNS & Neurological Disorders - Drug Targets
Title: Neuropeptides as Possible Targets in Sleep Disorders: Special Emphasis on Hypocretin-Deficient Narcolepsy
Volume: 6 Issue: 1
Author(s): Nobuhiro Fujiki and Seiji Nishino
Affiliation:
Keywords: Sleep disorders, neuropeptide, GPRC, hypocretin, orexin, narcolepsy
Abstract: Sleep disorders are disturbances of usual sleep patterns or behaviors caused by deregulation of neuronal synchronicity and of the balance of the neurotransmitter system involved in sleep regulation. Insomnia and hypersomnia are frequent sleep disorders, and these are most often treated pharmacologically with hypnotics and wake-promoting compounds. These compounds act on classical neurotransmitter systems, such as benzodiazepines on gamma amino butyric acid (GABA)A receptors, and amphetamine-like stimulants on monoaminergic terminals to modulate neurotransmission. In addition, acetylcholine, amino acids, lipids and proteins (cytokines) and peptides, are known to significantly modulate sleep, and thus, are possibly involved in the pathophysiology of some sleep disorders. Due to recent developments in molecular biological techniques, many neuropeptides have been newly identified, and some are found to significantly modulate sleep. Recent discoveries also include the finding that the impairment of hypocretin/orexin neurotransmission (a recently isolated hypothalamic neuropeptide and receptor system), is the major pathophysiology of narcolepsy with cataplexy. A hypocretin replacement therapy is anticipated to reverse the disease symptoms in humans. In this article, we will review the history of neuropeptide research, sleep modulatory effects of various neuropeptides, and the general strategies for the pharmacological therapeutics targeting the peptidergic systems by referring to hypocretin-deficient narcolepsy as an immediate example.
Export Options
About this article
Cite this article as:
Fujiki Nobuhiro and Nishino Seiji, Neuropeptides as Possible Targets in Sleep Disorders: Special Emphasis on Hypocretin-Deficient Narcolepsy, CNS & Neurological Disorders - Drug Targets 2007; 6 (1) . https://dx.doi.org/10.2174/187152707779940781
DOI https://dx.doi.org/10.2174/187152707779940781 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Screening and Identification of Differentially Expressed Genes Between Diabetic Nephropathy Glomerular and Normal Glomerular via Bioinformatics Technology
Combinatorial Chemistry & High Throughput Screening Molecular Modelling and QSAR in the Discovery of HIV-1 Integrase Inhibitors
Current Computer-Aided Drug Design Immunological Tolerance Using Synthetic Peptides - Basic Mechanisms and Clinical Application
Current Molecular Medicine Cholesterol, Lipids, Amyloid Beta, and Alzheimers
Current Alzheimer Research Conference Report: 10th International Summer School of Neurology: Celebrating a Decade of Success: 5th July, 2015 – 9th July, 2015 | Eforie Nord, Romania
CNS & Neurological Disorders - Drug Targets Age-related Differences in Mu Rhythm During Emotional Destination Memory Task
Current Aging Science Obstructive Sleep Apnea and Stroke
Current Respiratory Medicine Reviews The Many Faces of Aβ: Structures and Activity
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Neurotrophin Receptor Signaling as a Therapeutic Target for Huntington's Disease
CNS & Neurological Disorders - Drug Targets Bioprospecting for Functionally-Proficient Potential Probiotics
Current Nutrition & Food Science Metabolomic Approach in Probing Drug Candidates
Current Topics in Medicinal Chemistry Cofilin/Actin Rod Formation by Dysregulation of Cofilin-1 Activity as a Central Initial Step in Neurodegeneration
Mini-Reviews in Medicinal Chemistry APP/PS1 Gene-Environment Noise Interaction Aggravates AD-like Neuropathology in Hippocampus <i>Via</i> Activation of the VDAC1 Positive Feedback Loop
Current Alzheimer Research Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Role of Azoles in Cancer Prevention and Treatment: Present and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry Insulin Resistance and Endothelial Dysfunction: A Mutual Relationship in Cardiometabolic Risk
Current Pharmaceutical Design Effects and Perspectives of Chinese Patent Medicines for Tonifying <i>Qi</i> and Promoting Blood Circulation on Patients with Cerebral Infarction
Current Vascular Pharmacology Role of PGE2 and EP Receptors in the Pathogenesis of Rheumatoid Arthritis and as a Novel Therapeutic Strategy
Endocrine, Metabolic & Immune Disorders - Drug Targets SUBJECT INDEX
Current Neuropharmacology Herbal Medicine for Anxiety, Depression and Insomnia
Current Neuropharmacology